You are here

Roche says 2017 profit growth unlikely to outstrip sales

BT_20170202_ROCHE2PQ9X_2721173.jpg
Mr Schwan is playing down the threat posed by US President Donald Trump's call for drugmakers to cut prices and invest more in America, arguing that innovative companies will still be rewarded.

Zurich

ROCHE on Wednesday forecast that profit growth would not outstrip sales in 2017 as the world's top cancer drugmaker increases spending on new products that it hopes will offset declines in ageing biotech medicines now going off patent.

The Swiss drugmaker dismissed

sentifi.com

Market voices on:

Powered by GET.comGetCom